{"id":40469,"date":"2025-09-01T14:26:18","date_gmt":"2025-09-01T06:26:18","guid":{"rendered":"https:\/\/flcube.com\/?p=40469"},"modified":"2025-09-01T14:26:19","modified_gmt":"2025-09-01T06:26:19","slug":"suzhou-zelgen-secures-fda-approval-for-dual%e2%80%91targeted-therapy-trial-in-advanced-solid-tumors","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=40469","title":{"rendered":"Suzhou\u202fZelgen Secures FDA Approval for Dual\u2011Targeted Therapy Trial in Advanced Solid Tumors"},"content":{"rendered":"\n<p>Suzhou Zelgen Biopharmaceuticals Co., Ltd. (<a href=\"https:\/\/www.google.com\/finance\/quote\/688266:SHA\">SHA: 688266<\/a>) announced that the U.S. Food and Drug Administration (FDA) has approved a clinical trial combining its novel bispecific antibody <strong>ZG005<\/strong> with the bifunctional fusion protein <strong>ZGGS18<\/strong> for the treatment of advanced solid tumors.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-what-the-trial-entails\">What the Trial Entails<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>ZG005<\/strong> is a recombinant humanized anti\u2011PD\u20111\/TIGIT bispecific antibody (BsAb). It represents a Category\u202f1 therapeutic biologic for tumor immunotherapy and is the first drug of its kind with this dual checkpoint blockade mechanism to receive FDA clearance.<\/li>\n\n\n\n<li><strong>ZGGS18<\/strong> is a recombinant humanized anti\u2011VEGF\/TGF\u2011\u03b2 bifunctional antibody fusion protein, also a Category\u202f1 therapeutic biologic. It targets tumor angiogenesis while modulating the tumor microenvironment to enhance immune infiltration.<\/li>\n<\/ul>\n\n\n\n<p>The combination aims to simultaneously unleash T\u2011cell activity and disrupt the tumor vasculature, potentially overcoming resistance seen with single\u2011target agents.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-significance-for-suzhou-zelgen\">Significance for Suzhou\u202fZelgen<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Regulatory Milestone<\/strong> \u2013 FDA approval of the trial design marks a pivotal step toward bringing the therapy to U.S. patients and sets the stage for broader global development.<\/li>\n\n\n\n<li><strong>Innovative Mechanism<\/strong> \u2013 No other approved drug combines PD\u20111\/TIGIT blockade with VEGF\/TGF\u2011\u03b2 inhibition, positioning Suzhou\u202fZelgen at the forefront of next\u2011generation immuno\u2011angiogenic therapy.<\/li>\n\n\n\n<li><strong>Commercial Potential<\/strong> \u2013 Successful outcomes could fast\u2011track the product to phase\u202fIII, accelerating commercialization in the high\u2011growth oncology market.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-next-steps\">Next Steps<\/h2>\n\n\n\n<p>Suzhou\u202fZelgen plans to begin patient enrollment in late 2025, focusing on solid tumors with high PD\u2011L1 expression and angiogenic profiles. The company is also exploring partnership opportunities with U.S. oncology leaders to support trial execution and eventual market launch.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/688266_20250830_AXO3.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688266_20250830_AXO3.\"><\/object><a id=\"wp-block-file--media-c0699c37-10fa-46ff-a54c-b1a40b0d01c1\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/688266_20250830_AXO3.pdf\">688266_20250830_AXO3<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/688266_20250830_AXO3.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-c0699c37-10fa-46ff-a54c-b1a40b0d01c1\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that the U.S. Food and Drug Administration&#8230;<\/p>\n","protected":false},"author":1,"featured_media":40471,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,62,28,905,246],"class_list":["post-40469","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cancer","tag-clinical-trial-approval-initiation","tag-multi-specific-antibodies","tag-sha-688266","tag-zelgen-biopharmaceuticals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Suzhou\u202fZelgen Secures FDA Approval for Dual\u2011Targeted Therapy Trial in Advanced Solid Tumors - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China\u2011based Suzhou\u202fZelgen Biopharmaceuticals (SHA: 688266) has received FDA clearance to launch a clinical trial combining its bispecific anti\u2011PD\u20111\/TIGIT antibody ZG005 with the bifunctional anti\u2011VEGF\/TGF\u2011\u03b2 fusion protein ZGGS18 for advanced solid tumors.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=40469\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Suzhou\u202fZelgen Secures FDA Approval for Dual\u2011Targeted Therapy Trial in Advanced Solid Tumors\" \/>\n<meta property=\"og:description\" content=\"China\u2011based Suzhou\u202fZelgen Biopharmaceuticals (SHA: 688266) has received FDA clearance to launch a clinical trial combining its bispecific anti\u2011PD\u20111\/TIGIT antibody ZG005 with the bifunctional anti\u2011VEGF\/TGF\u2011\u03b2 fusion protein ZGGS18 for advanced solid tumors.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=40469\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-01T06:26:18+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-01T06:26:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0104.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40469#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40469\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Suzhou\u202fZelgen Secures FDA Approval for Dual\u2011Targeted Therapy Trial in Advanced Solid Tumors\",\"datePublished\":\"2025-09-01T06:26:18+00:00\",\"dateModified\":\"2025-09-01T06:26:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40469\"},\"wordCount\":275,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40469#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0104.webp\",\"keywords\":[\"Cancer\",\"Clinical trial approval \\\/ initiation\",\"Multi-specific antibodies\",\"SHA: 688266\",\"Zelgen Biopharmaceuticals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40469#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40469\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=40469\",\"name\":\"Suzhou\u202fZelgen Secures FDA Approval for Dual\u2011Targeted Therapy Trial in Advanced Solid Tumors - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40469#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40469#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0104.webp\",\"datePublished\":\"2025-09-01T06:26:18+00:00\",\"dateModified\":\"2025-09-01T06:26:19+00:00\",\"description\":\"China\u2011based Suzhou\u202fZelgen Biopharmaceuticals (SHA: 688266) has received FDA clearance to launch a clinical trial combining its bispecific anti\u2011PD\u20111\\\/TIGIT antibody ZG005 with the bifunctional anti\u2011VEGF\\\/TGF\u2011\u03b2 fusion protein ZGGS18 for advanced solid tumors.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40469#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40469\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40469#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0104.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0104.webp\",\"width\":1080,\"height\":608,\"caption\":\"Suzhou\u202fZelgen Secures FDA Approval for Dual\u2011Targeted Therapy Trial in Advanced Solid Tumors\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40469#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Suzhou\u202fZelgen Secures FDA Approval for Dual\u2011Targeted Therapy Trial in Advanced Solid Tumors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Suzhou\u202fZelgen Secures FDA Approval for Dual\u2011Targeted Therapy Trial in Advanced Solid Tumors - Insight, China&#039;s Pharmaceutical Industry","description":"China\u2011based Suzhou\u202fZelgen Biopharmaceuticals (SHA: 688266) has received FDA clearance to launch a clinical trial combining its bispecific anti\u2011PD\u20111\/TIGIT antibody ZG005 with the bifunctional anti\u2011VEGF\/TGF\u2011\u03b2 fusion protein ZGGS18 for advanced solid tumors.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=40469","og_locale":"en_US","og_type":"article","og_title":"Suzhou\u202fZelgen Secures FDA Approval for Dual\u2011Targeted Therapy Trial in Advanced Solid Tumors","og_description":"China\u2011based Suzhou\u202fZelgen Biopharmaceuticals (SHA: 688266) has received FDA clearance to launch a clinical trial combining its bispecific anti\u2011PD\u20111\/TIGIT antibody ZG005 with the bifunctional anti\u2011VEGF\/TGF\u2011\u03b2 fusion protein ZGGS18 for advanced solid tumors.","og_url":"https:\/\/flcube.com\/?p=40469","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-01T06:26:18+00:00","article_modified_time":"2025-09-01T06:26:19+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0104.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=40469#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=40469"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Suzhou\u202fZelgen Secures FDA Approval for Dual\u2011Targeted Therapy Trial in Advanced Solid Tumors","datePublished":"2025-09-01T06:26:18+00:00","dateModified":"2025-09-01T06:26:19+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=40469"},"wordCount":275,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=40469#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0104.webp","keywords":["Cancer","Clinical trial approval \/ initiation","Multi-specific antibodies","SHA: 688266","Zelgen Biopharmaceuticals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=40469#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=40469","url":"https:\/\/flcube.com\/?p=40469","name":"Suzhou\u202fZelgen Secures FDA Approval for Dual\u2011Targeted Therapy Trial in Advanced Solid Tumors - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=40469#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=40469#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0104.webp","datePublished":"2025-09-01T06:26:18+00:00","dateModified":"2025-09-01T06:26:19+00:00","description":"China\u2011based Suzhou\u202fZelgen Biopharmaceuticals (SHA: 688266) has received FDA clearance to launch a clinical trial combining its bispecific anti\u2011PD\u20111\/TIGIT antibody ZG005 with the bifunctional anti\u2011VEGF\/TGF\u2011\u03b2 fusion protein ZGGS18 for advanced solid tumors.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=40469#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=40469"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=40469#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0104.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0104.webp","width":1080,"height":608,"caption":"Suzhou\u202fZelgen Secures FDA Approval for Dual\u2011Targeted Therapy Trial in Advanced Solid Tumors"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=40469#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Suzhou\u202fZelgen Secures FDA Approval for Dual\u2011Targeted Therapy Trial in Advanced Solid Tumors"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0104.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40469","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=40469"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40469\/revisions"}],"predecessor-version":[{"id":40472,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40469\/revisions\/40472"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/40471"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=40469"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=40469"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=40469"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}